- Home
- HAYW vs RYTM Comparison
HAYW vs RYTM Comparison
Compare HAYW & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAYW
- RYTM
- Stock Information
- Founded
- HAYW 1925
- RYTM 2008
- Country
- HAYW United States
- RYTM United States
- Employees
- HAYW N/A
- RYTM N/A
- Industry
- HAYW Electronic Components
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- HAYW Technology
- RYTM Health Care
- Exchange
- HAYW Nasdaq
- RYTM Nasdaq
- Market Cap
- HAYW 3.2B
- RYTM 3.1B
- IPO Year
- HAYW 2021
- RYTM 2017
- Fundamental
- Price
- HAYW $16.06
- RYTM $56.23
- Analyst Decision
- HAYW Hold
- RYTM Strong Buy
- Analyst Count
- HAYW 5
- RYTM 10
- Target Price
- HAYW $16.80
- RYTM $62.30
- AVG Volume (30 Days)
- HAYW 2.4M
- RYTM 661.2K
- Earning Date
- HAYW 10-29-2024
- RYTM 11-05-2024
- Dividend Yield
- HAYW N/A
- RYTM N/A
- EPS Growth
- HAYW 40.94
- RYTM N/A
- EPS
- HAYW 0.43
- RYTM N/A
- Revenue
- HAYW $1,003,000,000.00
- RYTM $112,530,000.00
- Revenue This Year
- HAYW $5.29
- RYTM $63.95
- Revenue Next Year
- HAYW $7.08
- RYTM $43.24
- P/E Ratio
- HAYW $37.36
- RYTM N/A
- Revenue Growth
- HAYW 3.09
- RYTM 81.55
- 52 Week Low
- HAYW $11.54
- RYTM $31.53
- 52 Week High
- HAYW $16.87
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- HAYW 58.24
- RYTM 51.46
- Support Level
- HAYW $15.88
- RYTM $47.61
- Resistance Level
- HAYW $16.22
- RYTM $68.58
- Average True Range (ATR)
- HAYW 0.52
- RYTM 3.32
- MACD
- HAYW -0.05
- RYTM 0.27
- Stochastic Oscillator
- HAYW 39.10
- RYTM 41.11
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.0 billion in revenue in 2023.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.